Prognostic Biomarkers in Patients With Endometrial Cancer

Completed

Conditions studied: Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer

In brief

This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

Key facts

Study ID

NCT01208467

Run by

Gynecologic Oncology Group

People needed

2824

Starts

2010-09-01

Last updated by the study team

2017-08-23

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women who were eligible and evaluable for the GOG-0210 molecular staging protocol in women with endometrial cancer
• Women who were registered during the unrestricted enrollment period (through 9/23/07) will automatically qualify
• Women who were registered during the restricted enrollment period (after 9/23/07) will only be considered if needed
• Women who had histologically confirmed endometrioid endometrial adenocarcinoma regardless of stage or grade
• Women who have defective DNA mismatch repair and are microsatellite instability positive (MSI+ and MSI-low)
• Women who consented to allow their specimens and clinical data to be used for future cancer research
• Women who have sufficient high-quality genomic DNA from tumor available for mutation analysis of ATR

Where it is running

• Gynecologic Oncology Group — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.